Patents Examined by Valarie E Bertoglio
  • Patent number: 12778983
    Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.
    Type: Grant
    Filed: November 8, 2023
    Date of Patent: November 3, 2026
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Patent number: 12781189
    Abstract: This disclosure provides compositions comprising engineered ureteric bud kidney tissues and methods of making lumenized ureteric bud kidney tissues. Also provided herein are in vitro kidneys comprising nephron progenitor cells and ureteric bud cells. Methods of making the compositions and in vitro kidneys and uses thereof are disclosed herein. In some aspects, provided herein are methods for generating a lumenized kidney tissue having a spatially-controlled 3-dimensional (3D) tubular architecture in vitro.
    Type: Grant
    Filed: July 30, 2025
    Date of Patent: November 3, 2026
    Assignee: Trestle Biotherapeutics, Inc.
    Inventors: Benjamin Shepherd, Alice Chen, J. William Higgins, III
  • Patent number: 12766199
    Abstract: The present disclosure provides methods and compositions useful for the treatment or prevention of heart disease. In particular, the present disclosure provides a vector comprising a modified troponin T promoter operatively linked to a therapeutic gene product for the treatment or prevention of heart disease, e.g., cardiomyopathy. The gene product may be MYBPC3. The disclosure also provides recombinant adeno-associated virus (rAAV) virions, rAAV viral genomes, and expression cassettes and pharmaceutical compositions thereof. The disclosure further provides methods for treating a disease or disorder, such as heart disease.
    Type: Grant
    Filed: July 28, 2023
    Date of Patent: October 20, 2026
    Assignee: Tenaya Therapeutics, Inc.
    Inventor: Laura Lombardi
  • Patent number: 12767928
    Abstract: The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.
    Type: Grant
    Filed: September 29, 2023
    Date of Patent: October 20, 2026
    Assignee: IOVANCE BIOTHERAPEUTICS, INC.
    Inventors: Michelle R. Simpson-Abelson, Matthew J. Frigault, Wayne P. Rothbaum, Michael Weiser
  • Patent number: 12767930
    Abstract: In related-art methods of differentiating pluripotent stem cells into a desired cell type, there has not been established a differentiation induction method using human ES/iPS cells and being highly efficient. Many attempts have been made, including a stepwise differentiation induction method based on the control of culture conditions or the addition of, for example, various cell growth factors/differentiation factors to a culture solution, but the use of complicated culture steps is a big problem. A method of inducing differentiation into a desired cell type within a short period of time and with high efficiency by use of a pluripotent stem cell that actively undergoes cell differentiation, which is obtained by reducing an undifferentiated state of the pluripotent stem cell, has been developed, and thus the present invention has been completed.
    Type: Grant
    Filed: July 29, 2024
    Date of Patent: October 20, 2026
    Assignee: KEIO UNIVERSITY
    Inventor: Minoru Ko
  • Patent number: 12760271
    Abstract: The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions.
    Type: Grant
    Filed: February 29, 2024
    Date of Patent: October 13, 2026
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Jae-Won Shim, Sonja Kriks
  • Patent number: 12760272
    Abstract: Provided are a primary cell culture medium that contains a combination of an MST1/2 kinase inhibitor and a ROCK kinase inhibitor and is used for culturing primary esophageal squamous cell carcinoma epithelial cells, and a culture method using the primary cell culture medium. In the culture method, the primary cell culture medium is used to culture primary cells on a culture vessel coated with an extracellular matrix glue, so that the primary cells prolilferate rapidly. A cell model obtained by using the primary cell culture medium and the primary cell culture method of the present invention can be used for the efficacy evaluation and screening of drugs.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: October 13, 2026
    Assignee: PRECEDO PHARMACEUTICALS CO., LTD
    Inventors: Qingsong Liu, Jie Hu, Wenchao Wang, Cheng Chen, Tao Ren, Li Wang
  • Patent number: 12747278
    Abstract: The present invention relates to a novel chimeric antigen receptor and to a pharmaceutical composition for preventing or treating containing the same.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: September 29, 2026
    Assignees: SMT BIO CO., LTD., INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Yong Yoon Chung, In Hye Jung
  • Patent number: 12740550
    Abstract: Provided are genetically modified non-human animals that express a human or chimeric (e.g., humanized) TFR1, and methods of use thereof.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: September 22, 2026
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Chang Liu, Chengzhang Shang, Xiaofei Zhou
  • Patent number: 12742157
    Abstract: A method for generating a heart organoid is provided. The method includes forming a cellular aggregate of pluripotent stem cells, activating Wnt signaling in the cellular aggregate to cause the cellular aggregate to differentiate into a three-dimensional cardiac mesoderm, and inhibiting the Wnt signaling in the cardiac mesoderm to form the heart organoid. The heart organoid includes myocardial tissue, endocardial tissue defining at least one chamber, and epicardial tissue disposed on at least an outer surface of the myocardial tissue. The heart organoid beats. Heart organoids prepared in accordance with the method are also provided.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: September 22, 2026
    Assignee: Board of Trustees of Michigan State University
    Inventors: Aitor Aguirre, Yonatan Raz Israeli
  • Patent number: 12721892
    Abstract: The present invention provides chimeric antigen receptors (CAR) and methods of use in the treatment of diseases and disorders.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: September 1, 2026
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Gianpietro Dotti, Chuang Sun, Peishun Shou, Yang Xu
  • Patent number: 12697403
    Abstract: The present invention includes an engineered cell comprising a chimeric antigen receptor (CAR) further comprising a nucleic acid molecule comprising a suicide gene comprising a ligand binding domain and a suicide domain wherein the ligand binding domain is capable of binding to radiolabeled tracer or a small molecule suicide switch. This invention also includes methods for inducing apoptosis of an engineered cell, methods for assessing the efficacy or toxicity of an adoptive cell therapy in a subject, methods for detecting the quantity of engineered T cells in a subject, methods for monitoring an immunotherapy treatment in a subject and methods of imaging engineered T cells in a subject. In some embodiments, the imaging is performed via Positron Emission Topography (PET). This invention further includes a chemical inducer of dimerization (CID), wherein the CID is a Bis-Trimethoprim (Bis-TMP).
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: August 4, 2026
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Michael Farwell, Mark Sellmyer, Katheryn M. Lohith
  • Patent number: 12698513
    Abstract: Isolated guide RNA (gRNA) molecules comprising CRISPR (crRNA) molecules that target the 19:41869823_T_C mutation of a Ribosomal Protein S19 (RPS19) allele.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: August 4, 2026
    Assignee: EmendoBio Inc.
    Inventors: David Baram, Lior Izhar, Asael Herman, Rafi Emmanuel, Michal Golan Mashiach, Joseph Georgeson
  • Patent number: 12680081
    Abstract: The present invention relates to a human induced pluripotent stem cell line transformed with fluorescent protein-tagged CYP1A1 and an AHR modulator screening method using the same. Specifically, a human-induced pluripotent stem cell line (hiPSC line) in which a gene was edited to express a cytochrome P450 1A1 (CYP1A1) protein in a state of fusion with a fluorescent protein without inhibiting its unique function was prepared, and it was confirmed that an AHR modulator could be screened by screening cells in a living state using the cell line-derived liver cells better than in the case of using existing human primary hepatocytes (hPH) or HepG2 cells. Therefore, the CYP1A1-mCherry hiPSC cell line of the present invention can be effectively used for screening AHR modulating compounds.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: July 14, 2026
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Han-Jin Park, Ji-Woo Kim, Ilkyun Im, Hyemin Kim
  • Patent number: 12680082
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Grant
    Filed: January 9, 2023
    Date of Patent: July 14, 2026
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Patent number: 12674143
    Abstract: The present invention relates to a method for rescue of Vesicular Stomatitis Virus (VSV) from DNA in a HEK293 cell line or a HEK293 cell line adapted to suspension growth comprising (a) providing cells from a HEK293 cell line or a HEK293 cell line adapted to suspension growth in cell culture, (b) transfecting the cells with at least one plasmid, wherein the at least one plasmid comprises (i) an expression cassette comprising a VSV genomic cDNA; (ii) at least one expression cassette encoding VSV nucleoprotein (N) protein, VSV phosphoprotein (P) protein, and VSV large (L) protein; and (iii) an expression cassette encoding SV40 Large T antigen; (c) culturing the transfected cells; and (d) harvesting the cell culture supernatant comprising the rescued VSV.
    Type: Grant
    Filed: July 8, 2022
    Date of Patent: July 7, 2026
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Tobias Nolden
  • Patent number: 12674178
    Abstract: This disclosure describes a method that includes using dorsomorphin to increase the infectivity of adeno-associated virus (AAV). The AAV may be of any AAV serotype. In some embodiments, dorsomorphin may be used in combination with IL-6 or TNF? or both. This disclosure further describes methods for using dorsomorphin-treated cells to determine neutralizing antibody (NAb) titers.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: July 7, 2026
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Georgiy Aslanidi, Karina Krotova
  • Patent number: 12662685
    Abstract: Some embodiments provided herein relate to gene delivery systems and methods using a single plasmid that carries a self-inactivating transposase gene and a corresponding transposon. Some embodiments include nucleic acids having certain sequences, vector including such nucleic acids, and compositions including the vectors.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: June 23, 2026
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, Joshua Gustafson, Joseph Cheng, Rachel Wilson, Kamila Sabina Gwiazda, Jeremy Bjelajac
  • Patent number: 12661384
    Abstract: The present disclosure provides methods for inducing cell cycle reentry of postmitotic cell. The present disclosure further provides cells and compositions for treating diseases, such as cardiovascular diseases, neural disorders, hearing loss, and diabetes.
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: June 23, 2026
    Assignee: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
    Inventors: Tamer M. A. Mohamed, Deepak Srivastava
  • Patent number: 12655426
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. Compositions include fusion proteins between DNA binding proteins or protein domains and nucleic acid modifying proteins or protein domains. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, deaminases, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs. Also provided are deaminases which may be fused to a DNA-binding polypeptide and may be useful for gene editing.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: June 16, 2026
    Assignee: Life Edit Therapeutics, Inc.
    Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich, Mark Moore, Rodolphe Barrangou, Michael Lassner